

January 11, 2008  
Economic Times

# Venus Remedies to open R&D centre in Baddi

Rahul Kumar  
CHANDIGARH

VENUS Remedies is all set to commence the sixth and last phase of its Rs 150 crore expansion plan with the opening of its Medicine Research Centre in Baddi in Himachal Pradesh on January 14.

The company, which achieved a turnover of Rs 93.15 crore, in the first half of 2007-08 and Rs 144.75 crore in 2006-07 with exports worth Rs 23.79 crore, has set up a hi-tech research facility at Baddi. According to the company MD, Pawan Chaudhary, the unit will primarily focus on formulation research. He said the company would endeavour to undertake research and offer novel, innovative research products of world class quality and solutions for chronic and fatal diseases.

Mr Chaudhary said the new R&D centre, set up with an investment of Rs 25 crore, funded through internal accruals and borrowings from financial institutions, is spread over 40,000 sq feet built up area. It is proposed to be driven by a team of 50 intellectuals, including 25 scientists, pharmacists, chemists, analysts and technicians.

He said the research centre's activities will span the development and transfer of technology for Novel drug Delivery Systems (NDDS) and safe FDC (fixed dose combination) for injections, capturing of technologies from around the globe and developing products based on that technology, development of new sustained release formulations, analytical and chemical research, microbiological research, clinical studies including

pharmaco-kinetic and pharmaco-dynamic studies as its key focus areas.

The centre has 7 dedicated pilot plants, built as per latest international standards for conducting trial batches for injections in dry powder, ampule, liquid vials, lyophilised injections in vials and ampoules, vaccines, biological injectables and peptide based injectables.

Mr Chaudhary told ET here today that the research centre has eight fully equipped laboratories to cater all kinds of testing in-house including instrumentation, pharmacology and pharmacognosy, stability - with 7 stability chambers to test all four zone stability conditions as specified in ICH guidelines, toxicological studies, analytical and biochemical experiments, microbiological experiments, animal cell culture and sterility testing.

He said Venus has created this centre in order to be able to sustain and replenish its

pipeline of research products and deliver novel formulations to the market as per its needs. The company, he said, has an ambitious target of achieving Rs 500 crore sales turnover by 2,010 on the strength of its R&D.

During the current fiscal he said the company expects the turnover to exceed Rs 200 crore. He said the company has already launched three innovative formulations developed by its research wing which have become segment leaders. A pipeline of 70 products is already under various stages of development with the company with 6 Patent Applications in process world wide. The company has a policy of spending close to 5% of its turnover on research every year.



The Financial Express

## Venus R&D centre to commence on Jan 14

Charanjit Ahuja  
Chandigarh, Jan 10

Chandigarh-based Venus Remedies, winner of Express-ICICI "Emerging India Award", is set to commence the sixth and last phase of its Rs 150 crore expansion plan, with the inauguration of Venus Medicine Research Centre (VMRC) at Baddi, Himachal Pradesh on January 14.

Chairman of Venus Remedies, Pawan Chaudhary said on Thursday that the company was bringing up a hi-tech elaborate research facility at Baddi. Keeping in line with its focus on formulation research, the motto of the research program of the company is "Commitment to offer novel, innovative research products of world class quality, and solutions for chronic and fatal diseases".

This new R&D centre, which has been set up with an investment of about Rs 250 million, is spread over 40,000 sq. feet, in the Baddi campus of the company. It is driven by a team of 50 intellectuals, including 25 scientists, pharmacists, chemists, analysts and technicians.

This R&D centre will further strengthen the research capabilities of the company and help in building a stronger pipeline of solutions for diseases for which there is no present treatment. The company plans for accreditation of this center with the department of science and technology, government of India, as well as securing other certifications for the company.